Research and Development

Showing 15 posts of 9612 posts found.

eli_lilly_logo

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
keytruda1

MSD receives fourth Breakthrough Therapy Designation for Keytruda

April 19, 2016 Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
clinicaltrial

FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder

April 18, 2016 Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease

Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
novo_corp_hq2

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
tablet_production_2

British Biosimilars Association launches in UK

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association

A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
clinicaltrial1

Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics

April 18, 2016 Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology

Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
paris

Clinical trial initiated to help Paris attacks victims with PTSD

April 15, 2016 Medical Communications, Research and Development France, clinical trial, mcgill, mcgill university, terror attacks

Victims of the recent Paris terror attacks have been offered the opportunity to take part in a clinical trial, organised …
hospital

Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump

April 15, 2016 Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids

Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
shutterstock_211705468

US annual spending on drugs rose 12.2% in 2015 – IMS

April 15, 2016 Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending

The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
cancer_cells

Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer

April 15, 2016 Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university

Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …
clinical_trial_4

Synta Pharmaceuticals announces merger with Madrigal

April 15, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger

Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …

Merck says US FDA to review its Keytruda for head & neck cancer

April 14, 2016 Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda

The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
aedes_aegypti_mosquito

Zika causes microcephaly and other birth defects, says CDC

April 14, 2016 Medical Communications, Research and Development CDC, Zika, Zika virus, birth defects, microcephaly

The US Centers for Disease Control and Prevention has concluded that the Zika virus is a cause of microcephaly and …
merck-sharp--dohme-corp

Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials

April 14, 2016 Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier

US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
The Gateway to Local Adoption Series

Latest content